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Abstract
Background: Silicone breast implants have long been used for breast augmentation and reconstruction. During this time, these medical devices have
gone through a number of modiﬁcations to improve their safety, quality, and clinical outcome performance.
Objectives: The authors conducted a 10-year study to determine the safety and effectiveness of Natrelle 410 silicone breast implants.
Methods: This prospective, multicenter study enrolled 941 subjects who were undergoing either augmentation, augmentation revision, reconstruction,
or reconstruction revision. Data on complications, reoperations, explantations, and subject satisfaction were collected at annual clinic visits, and one-third of
subjects underwent biennial magnetic resonance imaging (MRI) to screen for implant rupture. The authors used the Kaplan-Meier estimator to calculate
risk rates for local complications, reoperations, and explantations.
Results: Capsular contracture rates increased approximately 1% per year from the previously reported 6-year rates. The rates were signiﬁcantly lower
than those from the Natrelle round gel core study. The overall rate of conﬁrmed ruptured implants in subjects who underwent MRI was 5.7%. Eleven late
seromas were reported. The most common reason for explantation was a subject requesting a size or style change. Satisfaction rates remained high
through 10 years, with most subjects saying they were somewhat or deﬁnitely satisﬁed with their implants.
Conclusions: This 10-year prospective trial demonstrated the long-term safety and effectiveness of Natrelle 410 anatomical form-stable implants. The
complication rates were low and the satisfaction rates were high.
Level of Evidence: 1
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Silicone gel–ﬁlled breast implants have been commercially
available for 50 years.1 During this time, these medical
devices have gone through a number of modiﬁcations to
improve their safety, quality, and clinical outcome performance. The most objective clinical assessment of these
outcome parameters in the United States was obtained
from investigational device exemption studies that were
approved by the US Food and Drug Administration (FDA).
These exemptions allowed use of medical devices in American
women before FDA approval when there was a speciﬁc
need. The Natrelle 410 anatomical form-stable silicone-ﬁlled
breast implant (Allergan, Inc., Irvine, California), which was
introduced in Europe in 1993 as the Biodimensional Style
410 implant, was the ﬁrst anatomically shaped silicone
implant to be designed and brought to the market.
The initial 3-year and subsequent 6-year clinical data on
these implants from an investigational device exemption
study initiated in February 2001 have been published previously.2,3 The Natrelle 410 silicone gel breast implants were
approved by the FDA on February 20, 2013, and the 10-year
study supporting their approval has been completed. The
present report provides updated clinical data through the
completion of the study and represents the ﬁrst publication
of a completed investigational device exemption study that
provides prospective, long-term data on highly cohesive,
form-stable breast implants.

METHODS
In this 10-year prospective, multicenter study, we examined
the safety and effectiveness of Natrelle 410 breast implants for
augmentation, reconstruction, and revision. Written informed
consent was obtained from all subjects, and multiple institutional review boards provided approval. (the list of the approving institutional review boards is available online at http://
asj.oxfordjournals.org/supplemental.) The study was registered at ClinicalTrials.gov (identiﬁer: NCT00690339). Before
the study was initiated, the study sponsor (Allergan, Inc.) conducted a start-up meeting at each investigational site and also
provided written instructions to investigators and study coordinators. In addition, site visits were conducted throughout
the study to ensure adherence to study guidelines.
The study design, inclusion/exclusion criteria, subject
demographics, surgical details, and safety and effectiveness
results through 6 years have been published previously;2–4
thus, the present report will focus on the 10-year results.
Data were captured prospectively at the initial clinic visit
and at visits 4 weeks and 6 months after implantation, as
well as annually thereafter for 10 years. Magnetic resonance imaging (MRI) was conducted 1, 3, 5, 7, and 10
years after implantation in a subset of subjects to assess
silent rupture, with the worst-case rupture assessment by
either the local facility radiologist or central reviewer radiologist used to calculate rupture rates. Kaplan-Meier risk

rates were calculated for local complications, reoperations,
and implant removal/replacement. These risk rates represent the cumulative risk of a subject experiencing an
adverse event at any time through 10 years. The primary
measure of effectiveness at 10 years was subject satisfaction. At each study visit, subjects were queried verbally
about satisfaction by the investigator or study coordinator,
and their responses were recorded on a case report form.
Subject satisfaction was evaluated using a nonvalidated
5-point scale ranging from 1 (deﬁnitely dissatisﬁed) to 5
(deﬁnitely satisﬁed).

RESULTS
Subjects
Between February 2001 and February 2002, we enrolled 941
women (492 undergoing primary augmentation, 156 undergoing augmentation revision, 225 undergoing primary
reconstruction, and 68 undergoing reconstruction revision)
at 48 US sites. Of those, 316 subjects were included in the
MRI cohort. More than 90% of subjects were white, and the
median body mass indices (weight in kilograms divided by
height in meters squared) were 20.6, 21.0, 22.6, and 22.4 in
the augmentation, augmentation revision, reconstruction,
and reconstruction revision cohorts, respectively.
For subjects undergoing breast augmentation, the indication for implant placement was dissatisfaction with breast
size/shape in 79.1%, asymmetry in 10.6%, ptosis in 6.7%,
and aplasia in 3.7%. All of the reconstruction procedures
occurred after mastectomy except for 1 that was performed
after breast trauma. Concurrent procedures were performed
in 7.2% of augmentation, 75.2% of augmentation revision,
53.7% of reconstruction, and 75.2% of reconstruction revision surgeries, with capsulectomies being the procedure
most often performed. Accompanying mastopexies were
performed in 6.6% of augmentation procedures and 17.7%
of augmentation revision procedures.
The inframammary fold was the most common incision
site for women undergoing augmentation (86.8%) or augmentation revision (75.5%), whereas the mastectomy scar
was the most common incision site for women undergoing
reconstruction (74.9%) or reconstruction revision (54.0%).
Partial submuscular placement was the most frequent location in all cohorts (80.5%, 65.8%, 59.9%, and 60.2% for
the augmentation, augmentation revision, reconstruction,
and reconstruction revision cohorts, respectively). In the
augmentation and augmentation revision cohorts, subglandular placement was the second most frequent placement (15.7% and 28.4%, respectively), whereas in the
reconstruction and reconstruction revision cohorts, it was
complete submuscular placement (27.7% and 31.9%,
respectively).
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Pocket irrigation with administration of medications
(most commonly antibiotics) was performed for the majority
of surgeries (61.1%, 66.5%, 79.4%, and 84.1% for the
augmentation, augmentation revision, reconstruction, and
reconstruction revision cohorts, respectively). Most subjects also received parenteral antibiotics (88.6% for women
undergoing augmentation, 93.6% for women undergoing
augmentation revision, 93.3% for women undergoing
reconstruction, and 97.1% for women undergoing reconstruction revision. Drains were placed in 4.3%, 45.2%,
65.5%, and 61.9% of the augmentation, augmentation revision, reconstruction, and reconstruction revision surgeries, respectively.
Follow-up rates at 10 years were 65.8% in the augmentation cohort, 55.3% in the augmentation revision cohort,
81.1% in the reconstruction cohort, and 78.4% in the
reconstruction revision cohort. The by-implant compliance
rate for the 10-year MRI was 70.1% for augmentation,
64.2% for augmentation revision, 72.3% for reconstruction, and 80.0% for reconstruction revision subjects.

Safety
Capsular contracture rates (Baker scale grades III and IV)
by subject increased approximately 1% per year from the
previously reported 6-year rates.3 The ﬁnal 10-year rates
were 9.2% for augmentation, 11.9% for augmentation revision, 14.5% for reconstruction, and 26.8% for reconstruction revision (Table 1, Figure 1). The overall rupture rate
(suspected and conﬁrmed) in the MRI cohort was 16.4%
(9.7% of implants). Of the 38 implants included as suspected ruptures, 26 were conﬁrmed to have ruptured at
explantation and 12 remained in vivo, so the rupture was
unconﬁrmed. Of those, 8 had MRI evidence of a probable
rupture and 4 had indeterminate MRI evidence. In the MRI
cohort across all indications, 9.4% of subjects had ruptures
and 5.7% of implants ruptured (Table 1, Figure 2). All of
the ruptures were intracapsular, with no reports of extracapsular rupture or migrated gel.
The rates of all complications remained low through 10
years, aside from capsular contracture and rupture in <5%
of women undergoing augmentation. For women who
underwent augmentation revision, the only other major
complications (>5%) were implant malposition (9.1%) and
asymmetry (6.9%). The seroma rate ranged from 1.6% in
augmentation subjects to 6.2% in reconstruction revision
subjects. Eleven seromas occurred >1 year after implantation, which means that 0.6% of the 1760 devices implanted
developed a late seroma (ranging from 0.4% in augmentation subjects to 0.9% in reconstruction revision subjects).
Onset dates for these seromas ranged from 1.4 to 7.6 years
after implantation, with most occurring at approximately
6 years.
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A single case of breast implant–associated anaplastic
large cell lymphoma (BIA-ALCL) was reported. The subject
had a strong family history of breast cancer and ﬁbrocystic
disease and had been diagnosed with intraductal hyperplasia before a simple mastectomy. She had undergone breast
reconstruction and was in the 10th year of her follow-up
when treatment of a late seroma led to the discovery of
ALCL. The cells were detected in the seroma ﬂuid and the
subject underwent bilateral implant removal and complete
capsulectomies. No tumor cells were detected in the capsules, the subsequent positron emission tomography scan
was normal, and no adjuvant treatment was given. The
subject has shown no evidence of recurrence in 3 years of
follow-up.
Reoperation rates increased approximately 3% per year
from the 6-year rates, and the most common reasons for
reoperation were subjects requesting a style or size change
(augmentation), capsular contracture and implant malposition (augmentation revision), scarring (reconstruction), and
capsular contracture (reconstruction revision). Explantations
were most often performed in response to subjects requesting a style or size change in all cohorts except the reconstruction revision cohort, in which capsular contracture resulted
in more explantations (Table 2). No gel fractures were
reported at explantation. Eighty-seven percent of subjects
had their implants replaced after removal, and of those who
had another 410 implant as the replacement, 60% went to a
larger implant, whereas 15% went to a smaller implant.
Investigators performed device assessments and reported
that at 10 years, the shape of the breast reﬂected the shape
of the implant for 97.3%, 95.8%, 91.8%, and 100% of the
augmentation, augmentation revision, reconstruction, and
reconstruction revision cohorts, respectively. Similarly,
they reported that the implants had maintained their original position for 96.9%, 93.0%, 94.8%, and 94.9% of
subjects, respectively. This was visually demonstrated with
photographic examples of subjects at baseline and at
10 years, along with an accompanying MRI image from the
10-year visit (Figures 3–6).

Satisfaction
Satisfaction rates remained high through 10 years, with
96.2%, 87.5%, 93.3%, and 90.0% of subjects saying they
were somewhat or deﬁnitely satisﬁed with their implants
for the augmentation, augmentation revision, reconstruction, and reconstruction revision cohorts, respectively
(Table 3). Investigators provided similarly high satisfaction
scores.

DISCUSSION
The Natrelle 410 implant was the ﬁrst ﬁfth-generation
breast implant developed,2 and it differs from prior
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Table 1. Kaplan-Meier Key Risk Rates by Subject Group Through 10 Yearsa
Complication

Augmentation Cohort,
% (95% CI) (n = 492)

Augmentation Revision Cohort,
% (95% CI) (n = 156)

Reconstruction Cohort,
% (95% CI) (n = 225)

Reconstruction Revision Cohort,
% (95% CI) (n = 68)

Reoperation

29.7 (25.6-34.3)

47.3 (39.2-56.0)

54.6 (47.9-61.6)

48.5 (37.0-61.5)

Implant removal with replacement

16.8 (13.6-20.8)

27.8 (21.0-36.2)

34.3 (28.0-41.6)

39.3 (28.2-52.9)

3.3 (1.9-5.7)

5.9 (2.8-12.2)

6.7 (3.8-11.7)

4.9 (1.2-18.7)

Implant rupture (MRI cohort)

17.7 (11.7-26.4)

14.7 (5.4-36.4)

12.4 (6.0-24.4)

19.6 (7.8-44.4)

Confirmed implant rupture (MRI cohort)

10.2 (6.0-17.0)

5.2 (1.3-19.4)

9.5 (4.4-19.9)

10.1 (2.6-34.7)

Capsular contracture (Baker grade III/IV)

9.2 (6.7-12.6)

11.9 (7.2-19.3)

14.5 (10.1-20.6)

26.8 (16.8-41.1)

Implant malposition

4.7 (3.1-7.3)

9.1 (5.2-15.6)

5.7 (3.1-10.5)

8.0 (3.0-20.5)

Breast pain

4.5 (2.8-7.1)

5.2 (2.3-11.5)

8.2 (4.9-13.7)

7.8 (2.9-20.4)

Swelling

4.0 (2.5-6.3)

2.7 (1.0-7.1)

5.3 (2.8-9.7)

3.2 (0.8-12.4)

Infection

1.7 (0.8-3.3)

2.1 (0.7-6.3)

6.1 (3.5-10.7)

8.5 (3.6-19.5)

Seroma/fluid accumulation

1.6 (0.8-3.3)

3.2 (1.2-8.4)

2.8 (1.1-6.6)

6.2 (2.4-15.8)

Hypertrophic/abnormal scarring

1.4 (0.6-3.0)

3.7 (1.5-8.8)

4.8 (2.6-8.7)

3.2 (0.8-12.3)

Hematoma

1.3 (0.6-2.9)

2.0 (0.6-6.0)

1.0 (0.3-4.0)

Delayed wound healing

1.1 (0.4-2.5)

1.3 (0.3-5.1)

0.5 (0.1-3.3)

2.9 (0.7-11.3)

Asymmetry

1.2 (0.5-2.9)

6.9 (3.6-13.1)

12.4 (8.4-18.1)

17.4 (9.6-30.5)

Wrinkling/rippling

0.9 (0.3-2.4)

3.7 (1.5-8.6)

6.2 (3.3-11.4)

12.8 (6.1-25.6)

Redness

0.6 (0.2-2.0)

0.9 (0.2-3.7)

4.9 (1.6-14.7)

Implant palpability/visibility

0.3 (0.0-1.8)

1.4 (0.3-5.4)

1.2 (0.3-4.7)

4.2 (1.0-16.5)

0.7 (0.1-4.5)

4.2 (2.2-7.8)

1.5 (0.2-10.1)

Key risk rates

Implant removal without replacement

Additional risk rates occurring in ≥2.0% of subjects

Upper pole fullness

0

0

0

a

CI, confidence interval; MRI, magnetic resonance imaging. Data are presented as rate (95% CI).

implants in a number of ways. Rather than a single-shaped,
mandrel-designed implant differentiated only by the size
(volume) of the round mandrel, the Natrelle 410 is anatomically shaped, with 12 dimensional options that allow for a
combination of 3 different heights and 4 different projections. This diversity of implant types (termed “cells”)
allows for an individualized approach to suit patient needs.
Four of the 12 cells were available and used for the current
investigational device exemption study: moderate height
and projection, full height and projection, moderate height
and full projection, and full height and moderate projection. The 410 implant is differentiated from the fourthgeneration implants by its highly cohesive, form-stable silicone gel ﬁller (TruForm 3 gel; Allergan, Inc.).5,6 A greater
degree of crosslinking of the silicone polymers during the
manufacturing process determines the ﬁrmness, or cohesivity, of the silicone gel. When oriented in a vertical position,

the 410 implants are said to be form-stable, maintaining
their dimensions and form (ie, gel distribution within the
shell), and are characterized by the lack of collapse of the
upper pole of the breast implant.5,6 The textured surface of
the 410 implant, termed Biocell (Allergan, Inc.), was speciﬁcally created to help maintain implant stability and position
within the body. Biocell is a macrotexture surface with irregular depressions that have an average diameter of 300 μm,7
and it demonstrates an adhesive effect with surrounding
native tissue after surgical implantation.8 Together, these
properties mark a distinct departure from previous generations of breast implants by providing adequate shape stability to prevent signiﬁcant implant collapse and a sufﬁciently
textured surface to help hold implant position.
One of the most commonly reported complications in
breast surgery is capsular contracture. The risk of this
complication increases over time9–11 and is reﬂected in the
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Figure 1. These Kaplan-Meier curves show the risk of capsular contracture through 10 years.

Figure 2. These Kaplan-Meier curves show the risk of implant rupture through 10 years. MRI, magnetic resonance imaging.

slightly increased capsular contracture rates reported herein
from 6 years to 10 years.3 However, the 10-year rates (9.2%,
11.9%, 14.5%, and 26.8% for the augmentation, augmentation revision, reconstruction, and reconstruction revision
cohorts, respectively) are lower than those observed in the
Natrelle round gel (fourth generation) core study, which included predominately smooth implants (56.2%).12 The capsular contracture rate for the 410 implant at 10 years was
51% lower (9.2% vs 18.9%) than that reported at 10 years
in the Natrelle round gel core study for primary breast augmentation.12 Further, a 59% lower incidence of capsular
contracture was noted for breast augmentation revision
with the 410 implant compared with the Natrelle round
gel implant (11.9% vs 28.7%, respectively) at 10 years.12
Similarly, in 6-year clinical trial data of the form-stable
Contour Proﬁle Gel (CPG) implant (Mentor Worldwide LLC,
Santa Barbara, California), lower contracture rates were reported for the CPG implant than for Mentor’s predominately
smooth-surface round gel breast implants.13 Although

these studies were not direct comparisons between formstable and non–form-stable implants and no causation can
be assigned, it is of interest that form-stable implants appeared to have lower rates of capsular contracture.
Careful preoperative planning and improvements in surgical technique also have been reported to decrease rates of
capsular contracture. Most 410 implants used for augmentation and augmentation revision in this study were placed
via an incision in the inframammary fold, which has been
independently shown to have lower capsular contracture rates
than other incision placement locations.14–16 Submuscular
placement and antibiotic pocket irrigation is advocated, as
well as the “no-touch” technique of implantation. Although it
cannot be documented that this process was utilized in every
subject in this study, these principles and techniques were
taught for the use of this implant and were conveyed to the
independent investigators. These factors have also been independently documented to reduce capsular contracture with
all implants.17,18

Aesthetic Surgery Journal 35(2)

150
Table 2. Primary Reasons for Reoperation and Explantation
Reason

% of Augmentation
Cohort

% of Augmentation
Revision Cohort

% of Reconstruction
Cohort

% of Reconstruction
Revision Cohort

Reasons for reoperation occurring in >8% of reoperations
No. of reoperations

167

83

163

40

Subject request for style/size change

13.2

8.4

7.4

10.0

Capsular contracture

11.4

14.5

12.3

22.5

Suspected rupture

11.4

12.0

9.8

7.5

Implant malposition

10.2

14.5

12.3

10.0

Scarring

9.0

8.4

19.0

2.5

Need for biopsy

8.4

13.3

7.4

5.0

Ptosis

7.8

8.4

3.7

0

Reasons for implant removal (with or without replacement) occurring in >8% of explantations
No. of explantations

153

78

115

40

Subject request for style/size change

34.0

24.4

20.9

20.0

Suspected rupture

13.7

16.7

14.8

7.5

Ptosis

11.1

5.1

1.7

0

Capsular contracture

9.8

23.1

15.7

25.0

Asymmetry

4.6

6.4

11.3

2.5

Implant malposition

4.6

9.0

11.3

7.5

Wrinkling/rippling

0.7

0

5.2

15.0

Incorporation of these techniques facilitates the characteristics of the implant, which reduces capsular contracture. The direct contact with the Biocell textured surface,
supported by the ﬁrmness of the highly cohesive gel, and
its engagement with a surgically created vascular host
pocket frequently allows for tissue adherence and immobility with softness.8,19 These ﬁndings, ﬁrst established with
Biocell tissue expanders, are more likely to occur with the
410 implant than with less cohesive, round, textured
implants in a less precise surgical pocket. Furthermore, the
reduced rate of capsular contracture with the Natrelle 410
implant and the clinically appreciated softness has been
described as providing a one breast feel as compared with
a round implant moving in its larger pocket separate from
the movement of the overlying breast and soft tissue.20
Although the ﬁrmer gel of the 410 implant could mask the
feel of some mild capsular contracture formation, it is clear
that when the 410 implant was used properly, it had the
lowest 10-year rate of capsular contracture of any implant
studied thus far in an FDA-approved registration trial. These
data also further supported the recent ﬁnding that Biocellcovered 410 implants have a statistically lower rate of

capsular contracture than do smooth fourth-generation
round gel implants used for primary augmentation.21 These
results are in agreement with those from previous publications, which showed improved rates of capsular contracture
in textured implants compared with smooth implants.22–28
Although these implants feel soft in the body, the
10-year data show a very low rate of implant rippling or
wrinkling (0.9% for augmentation, 3.7% for augmentation
revision, 6.2% for reconstruction, and 12.8% for reconstruction revision). These data corroborated previously
published data, which demonstrated that the Natrelle 410
implants have low rates of wrinkling compared with othershaped implants. Indeed, in a comparative study, Jewell
and Jewell29 reported a 5-fold higher rate of rippling in the
CPG implant group compared with the 410 implant group.
In a separate study of the 410 implant, wrinkling was
reported in 5% of subjects after a mean of 8 years.30
Another important ﬁnding in this 10-year study is the
low malposition rate of the shaped 410 implant, reported
herein at 4.7% for augmentation, 9.1% for augmentation
revision, 5.7% for reconstruction, and 8.0% for reconstruction revision. It should be noted that rotation is a subset of

Maxwell et al

151

Figure 3. This 33-year-old woman is shown before (A, C) and 10 years (B, D) after breast augmentation with 255-cc Natrelle 410
moderate height, full projection implants.

Figure 4. Magnetic resonance imaging scan taken 10 years
after breast augmentation with 255-cc Natrelle 410 moderate

malposition, and thus the rate of postoperative rotation is
even lower. This low malposition rate likely reﬂects the

utility of Biocell in maintaining the correct anatomical
alignment within the recipient and minimizing postoperative implant rotation.8,31 However, this tissue adherence to
the Biocell surface does not always occur, and therefore
rotation of the shaped device is possible. To this point, in a
recent study using high-resolution ultrasound rather than
MRI, Schafer et al32 reported higher-than-expected rotation
rates for shaped breast implants (21% and 25% for the 410
and CPG implants, respectively). The study authors noted
this was a dynamic process, with the majority of rotations
expected to self-reverse.33
The 10-year seroma rate was also quite low in our study
(1.6% for augmentation, 3.2% for augmentation revision,
2.8% for reconstruction, and 6.2% for reconstruction revision), with 11 seromas occurring >1 year after surgery
(0.6%). The conﬁrmed rupture rate in the MRI cohort for
all indications was 9.4% for subjects and 5.7% for implants
at 10 years, and there was no report of extracapsular silicone gel through the 10 years of the study.
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Figure 5. This 36-year-old woman is shown before (A, C) and 10 years after (B, D) breast reconstruction with a bilateral neopectoral pocket conversion and placement of 255-cc Natrelle 410 full height, full projection implants.

Figure 6. Magnetic resonance imaging scan taken 10 years after
breast reconstruction with a bilateral neopectoral pocket conversion and placement of 255-cc Natrelle 410 full height, full projection implants in the 36-year-old woman shown in Figure 5.

In recent years, increased awareness of BIA-ALCL, a rare
ALCL subset, has been noted. In 1 study, the incidence of
BIA-ALCL was estimated to be 0.1-0.3 per 100,000 women

with implants per year.34 Although the etiology of this
condition is not yet known, it is distinct from systemic
ALCL and typically characterized by early detection, an
indolent course, and high rates of complete remission after
treatment via implant removal and capsulectomy.35 Cases
of BIA-ALCL have been reported across implant types
(smooth, textured, saline, silicone), across manufacturers,
and in subjects with and without prior implant history;
however, more cases have been reported with texturedsurface devices. In the present study, 1 subject in her 10th
year of follow-up presented with BIA-ALCL that was
detected in seroma ﬂuid. She was conservatively treated
with bilateral capsulectomies and implant removal. She
remains disease-free without any evidence of recurrence.
Despite the many advantages reported herein of the
ﬁrmer, greater crosslinked silicone gel implant compared
with fourth-generation round implants, it has been questioned whether these implants impart a ﬁrmer feel within
the body. Perhaps one can accept this tradeoff for a lower
capsular contracture rate, with a documented safe implant,
and a better shape to the breast, particularly in subjects
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Table 3. Subject Satisfaction at 10 Years
Satisfaction Level

% of Augmentation Cohort

% of Augmentation Revision
Cohort

% of Reconstruction Cohort

% of Reconstruction Revision
Cohort

Definitely dissatisfied (1)

1.4

2.8

1.5

0

Somewhat dissatisfied (2)

2.1

8.3

2.2

7.5

Neither satisfied nor dissatisfied (3)

0.3

1.4

3.0

2.5

Somewhat satisfied (4)

7.2

16.7

17.9

22.5

Definitely satisfied (5)

89.0

70.8

75.4

67.5

who have minimal breast tissue and a tighter tissue envelope or in reconstruction subjects in whom the entire breast
is essentially an implant. Although our clinical data did not
directly capture subject-perceived ﬁrmness, 96.2% of augmentation subjects reported they were somewhat or deﬁnitely satisﬁed with their implants at 10 years. These
percentages were 87.5% for women who underwent augmentation revision, 93.3% for women who underwent
reconstruction, and 90.0% for women who underwent reconstruction revision. In addition, in an earlier publication
that focused on augmentation, Gladfelter and Murphy4
showed that women who had undergone augmentation
reported improved satisfaction with the feel of their breasts
after implantation. There were similar levels of improvement in subject satisfaction with regard to breast feel
among subjects who underwent reconstruction.
It is important to note that there is a potential for bias in
studies that rely on self-reported data. The investigators in
the present study were experienced surgeons who had speciﬁc experience with shaped breast implants. Although
there may be inconsistency in reporting among investigators within the study, individual investigators are likely to
be fairly consistent in their reporting. Despite the limitations inherent to studies such as this, the results of controlled, monitored studies are likely less biased than are
results obtained from retrospective reviews. It is also worth
noting that the present study was source data monitored
and conducted under the purview of the FDA.
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